A systematic review and meta-analysis of app-based interventions for chronic disease found that up to 80% of users engage only minimally, defined as logging in fewer than twice.
We are delighted to welcome Kenneth Jensen to Liva as our new Chief Product and Technology Officer.
GLP-1 receptor agonists work. On that, the evidence is clear and the clinical enthusiasm is justified. Semaglutide produces average weight loss of around 15% in trial conditions. HbA1c improves.
The return on investment of diabetes prevention is not the problem. The maths is not ambiguous. What is broken is the way most insurers are trying to calculate it.
The UK NHS waiting list stood at 7.4 million patients in early 2025, and private providers are absorbing a growing share of that demand.
Prediabetes affects up to 1 in 3 employees, silently. Here's what that costs your business, and how structured behaviour change programmes reverse the risk.
At a system level, access to digital health tools has expanded significantly. But access alone has never been the hard part. Sustained engagement is.
Early intervention reduces long-term costs, improves outcomes and eases pressure across the system. For everyone who carries the cost, acting earlier is simply the smarter choice.
Liva Healthcare and NUPO Support Groundbreaking National Diabetes Research in Denmark with cutting-edge Digital Technology and clinically formulated diet programme.
Long-term health outcomes are shaped between clinical visits, not during them. This article explores why behaviour change is the missing link in sustainable, scalable chronic care. (≈170 karakter)
The partnership is marking a significant step in expanding Liva Healthcare’s presence and impact in the GCC region.
Discover how asynchronous care is reshaping remote healthcare – offering flexible, scalable support for long-term conditions through structured digital tools and human coaching.
